Alpha1-Antitrypsin Deficiency research hub
4 indexed studies · 2 currently recruiting
- active not recruitingPHASE3
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease
This study looks at how safe a medicine called fazirsiran is for people with liver disease caused by a condition called Alpha-1 Antitrypsin Deficiency. It's for those who have been in previous fazirsiran studies and will check if the medicine helps their liver over a long time.
United States · Austria · Germany - recruitingPHASE3
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
This study investigates if a new drug called fazirsiran can help reduce liver scarring in people with Alpha-1 Antitrypsin Deficiency. Researchers also want to see if it slows liver disease, understand how it works in the body, and check for side effects.
United States · Australia · Austria - recruitingPHASE3
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
This study looks at a new medicine, fazirsiran, for people with a genetic liver condition called Alpha-1 Antitrypsin Deficiency, who have early liver scarring. It aims to see if the medicine is safe, well-tolerated, and can help reduce the abnormal protein buildup that causes liver damage.
United States · Austria · Belgium - authorisedTherapeutic use (Phase IV)
A Phase 4, Multicenter, Double-blind, Study to Investigate the Efficacy, Safety, and Tolerability of 3 Active Doses of Respreeza® / Zemaira® Weekly Intravenous Infusions Administered over 3 Years as Longterm Maintenance Therapy in Adult Subjects with Emphysema Related to Alpha1 Antitrypsin Deficiency
This study looks at a medicine called Respreeza to see how well it helps adults with a lung condition called emphysema caused by Alpha-1 Antitrypsin Deficiency. It checks if the medicine improves breathing and is safe when given weekly for three years.
Denmark